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We have developed a model system of human fibrosarcoma cell lines that do or do not possess and express
an oncogenic mutant allele of N-ras. HT1080 cells contain an endogenous mutant allele of N-ras, whereas the
derivative MCH603 cell line contains only wild-type N-ras. In an earlier study (S. Gupta et al., Mol. Cell. Biol.
20:9294–9306, 2000), we had shown that HT1080 cells produce rapidly growing, aggressive tumors in athymic
nude mice, whereas MCH603 cells produced more slowly growing tumors and was termed weakly tumorigenic.
An extensive analysis of the Ras signaling pathways (Raf, Rac1, and RhoA) provided evidence for a potential
novel pathway that was critical for the aggressive tumorigenic phenotype and could be activated by elevated
levels of constitutively active MEK. In this study we examined the role of phosphoinositide 3-kinase (PI
3-kinase) in the regulation of the transformed and aggressive tumorigenic phenotypes expressed in HT1080
cells. Both HT1080 (mutant N-ras) and MCH603 (wild-type N-ras) have similar levels of constitutively active
Akt, a downstream target of activated PI 3-kinase. We find that both cell lines constitutively express platelet-
derived growth factor (PDGF) and PDGF receptors. Transfection with tumor suppressor PTEN cDNA into
HT1080 and constitutively active PI 3-kinase–CAAX cDNA into MCH603 cells, respectively, resulted in several
interesting and novel observations. Activation of the PI 3-kinase/Akt pathway, including NF-kB, is not required
for the aggressive tumorigenic phenotype in HT1080 cells. Activation of NF-kB is complex: in MCH603 cells
it is mediated by Akt, whereas in HT1080 cells activation also involves other pathway(s) that are activated by
mutant Ras. A threshold level of activation of PI 3-kinase is required in MCH603 cells before stimulatory cross
talk to the RhoA, Rac1, and Raf pathways occurs, without a corresponding activation of Ras. The increased
levels of activation seen were similar to those observed in HT1080 cells, except for Raf and MEK, which were
more active than HT1080 levels. This cross talk results in conversion to the aggressive tumorigenic phenotype.
This latter observation is consistent with our previous observation that overstimulation of the activity of
endogenous members of Ras signaling pathways, activated MEK in particular, is a prerequisite for aggressive
tumorigenic growth.
Members of the Ras superfamily are small GTP-binding
proteins that function as activating transducers of signaling
pathways, whose members are commonly kinases or transcrip-
tion factors (3, 5). Three members of this family, namely,
H-ras, K-ras, and N-ras, have been implicated in human can-
cers. Mutations in ras alleles have been found in more than
30% of human cancers. The mutations invariably result in
chronic GTP binding to the Ras molecule and its consequent
chronic activation. This state results in constitutive activation
of Ras-dependent signaling pathways. Among these are the
Raf, Rac1, RhoA, and phosphoinositide (PI) 3-kinase signal
transduction cascades (29). These pathways have been shown
to regulate mitogenesis signals, motility and invasiveness, actin
cytoskeletal architecture, and cell survival, respectively (10, 21,
38, 39). Derangement of the normal regulation of these cellu-
lar processes, as occurs when mutant Ras proteins are ex-
pressed, is deleterious for the normal behavior of the cells in
question and contributes to the progression to a cancerous
state.
A variety of experimental procedures, usually utilizing ro-
dent cells, have shown that downstream members of each of
the signaling pathways identified above, when mutated, func-
tion as transforming oncogenes (23). Among these genes are
PI 3-kinase and its downstream target Akt, also known as
protein kinase B (2, 41). PI 3-kinase activates Akt, a serine
threonine kinase (25), which in turn phosphorylates a number
of substrates, including Bad, caspase 9, Forkhead transcription
factors, and IKKa (6, 9, 13, 33). Phosphorylation of Bad, pro-
caspase 9, and Forkhead transcription factors inactivates these
proapoptotic molecules, whereas phosphorylation of IKKa ac-
tivates this kinase, leading eventually to activation of the anti-
apoptotic NF-kB transcription factor. Each of these substrates
is implicated in cell survival. One of the major cell survival
factors is NF-kB, whose activation status is dependent upon
binding to the IkB protein. The IkB protein complexes with
NF-kB and sequesters it in the cytoplasm, thereby preventing
it from entering the nucleus. Degradation of IkB, following
phosphorylation by IKK, releases NF-kB, which then enters
the nucleus and activates its target genes (22, 40, 48). Activa-
tion of NF-kB is associated with increased cell survival and cell
proliferation (4, 49, 50). One proposed mechanism for the
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activation of IKK is phosphorylation mediated by Akt (33, 42).
However, other mechanisms also exist that do not involve the
degradation of IkB (27, 44).
In addition to being activated by Ras-GTP, PI 3-kinase may
also be activated directly by contact with activated growth
factor receptors, including platelet-derived growth factor
(PDGF) (20, 46). Dysregulated PI 3-kinase activity is likely to
play an important role in cancer progression. One indication of
this has been the identification of the PTEN tumor suppressor
gene (26, 45). PTEN is a common target of inactivating muta-
tions in a variety of sporadic human cancers. In addition, germ
line mutations in the PTEN gene are associated with Cowden’s
disease, an inherited hamartoma syndrome that includes an
elevated risk of breast and thyroid cancers (31). The PTEN
protein functions as both a protein and a lipid phosphatase. It
is the lipid phosphatase activity that is critical for its tumor-
suppressing function (30). PTEN lipid phosphatase catalyzes
the dephosphorylation of the 3 position of PI 3,4,5-triphos-
phate (PIP3) and PI 3,4,-biphosphate (PIP2), both of which are
the lipid byproducts of the lipid kinase activity of PI 3-kinase.
The Akt molecule binds to PIP3 via its pleckstrin homology
(PH) domain. In this complex with PIP3, Akt is then phos-
phorylated and activated by the PI-dependent kinase, PDK-1
(1, 8). Thus, normal cells integrate the activities of PI 3-kinase
and PTEN to facilitate homeostasis with respect to PI 3-ki-
nase-mediated signal transduction and cell cycle control. Over-
activation of PI 3-kinase or loss of PTEN function is likely to
cause dysregulation of this finely balanced control. An illustra-
tion of this is that expression of wild-type PTEN transfected
into PTEN-null cancer cells results in induction of G1 arrest
and/or apoptosis (12, 16). Conversely, this arrest can be over-
ridden by a constitutively active form of Akt (52, 55).
We have developed an experimental model system compris-
ing the human fibrosarcoma cell line HT1080, which possesses
one mutant N-ras allele, and its derivative, MCH603, which has
deleted the mutant allele and possesses only wild-type N-ras
(35). Examination of these cells has shown that HT1080 has a
typical transformed phenotype in culture, including disorga-
nized actin stress fibers and the ability to grow in soft agar, plus
an aggressive tumorigenic phenotype in vivo in immunodefi-
cient mice. By contrast, MCH603 cells have “reversed” their
transformed phenotype; they have restored a well-organized
actin stress fiber distribution in the cytoplasm and are no
longer able to grow in soft agar. When implanted into immu-
nodeficient mice they continue to form tumors but with much
slower kinetics. We have described these cells as having a weak
tumorigenic phenotype (35).
When we examined the activation of a number of Ras sig-
naling pathways, namely, the Raf, Rac1, and RhoA pathways,
we found that all members were constitutively active in
HT1080 but had basal activity in MCH603 cells (36). However,
we noted that Akt was constitutively active in both cell lines.
Since this was not due to oncogenic Ras expression in
MCH603 cells, we looked for another explanation. In this
study we found that both cell lines constitutively synthesize and
secrete PDGF and contain cell surface PDGF receptor
(PDGFR). Thus, this provides a mechanism for constitutive
activation of PI 3-kinase, resulting in the activation of Akt.
Although HT1080 and MCH603 cells have different trans-
formed and tumorigenic phenotypes and yet both have consti-
tutively active Akt, it is formally possible that there may be
quantitative and qualitative differences in the activation of PI
3-kinase and/or Akt and their downstream substrates in the
two cell lines that play a role in the expression of these phe-
notypes. In order to determine this, we have modulated the
activation of PI 3-kinase and Akt by stable transfection of
HT1080 and MCH603 cells with PTEN and an activated mu-
tant of PI 3-kinase (hereafter termed PI3Kact), respectively.
Examination of the biochemical and biological properties of
the parental and transfectant cells has revealed several unex-
pected and novel findings with respect to both signal transduc-
tion pathways and biological behavior.
MATERIALS AND METHODS
Molecular constructs. The expression plasmids used in this study were
as follows: PI3Kact-pCMV(hyg)P110CAAX59myc is derived from pSG5P110
CAAX59myc (51) and encodes the catalytic domain of PI 3-kinase. The consti-
tutively active protein product, PI3Kact, is permanently plasma membrane asso-
ciated. The construct pCDNA3PTEN(wt) (Neo) encodes a full-length wild-type
PTEN cDNA (52), whose expression is driven from a heterologous cytomegalo-
virus promoter.
Cell culture and stable transfection. The HT1080 cell line has one mutant and
one wild-type N-ras allele (28, 35). MCH603 is a variant of HT1080 and contains
only wild-type N-ras (35). The cell lines were maintained in Dulbecco minimal
essential medium (DMEM) supplemented with 10% fetal calf serum (FCS; Life
Technologies). The HT1080 and MCH603 cell lines were transfected with the
PTEN(wt) and PI3Kact plasmids, respectively. Clones from each transfection
were selected and maintained in medium containing the relevant selective anti-
biotic (either 800 mg of Geneticin [Gibco-BRL] or 36 U of hygromycin B
[Calbiochem] per ml for the HT1080 and MCH603 transfectants, respectively).
Subconfluent (70%) 100-mm dishes of MCH603 cells or HT1080 cells were
transfected with 5 mg of linearized DNA or vector control DNA, using 30 ml of
Lipofectin (Gibco-BRL) in Optimem medium (Gibco-BRL).
Growth in soft agar. Logarithmically growing cells (104 or 106) were plated in
single-cell suspension in a 0.3% top agar overlay in DMEM supplemented with
10% FCS, above a 0.5% bottom agar layer (in DMEM–10% FCS) in 60-mm
dishes as previously described (35). Plates were fed periodically with 1 ml of
DMEM–10% FCS. Colonies (.0.1 mm) were inspected under the microscope
and counted after 3 weeks.
Actin cytoskeleton staining and morphology. Cells grown on glass slides
(Nunc) were washed with phosphate-buffered saline (PBS) and fixed with 3.7%
paraformaldehyde in PBS for 10 min. After a wash with PBS, cells were perme-
abilized with PBS containing 0.1% Triton X-100 for 5 min. The slides were then
washed, and the actin stress fibers were visualized by staining the cells with
fluorescein-conjugated phalloidin (0.005 U/ml; Molecular Probes) for 20 min at
room temperature and mounted in ProLong Fade antifade (Molecular Probes).
Immunoblot analyses. Subconfluent cells were serum starved for 18 h, and the
cells were then lysed in lysis buffer comprised of 1% sodium dodecyl sulfate
(SDS) in 20 mM Tris (pH 7.4), 1 mM CaCl2, 1 mM phenylmethylsulfonyl
fluoride, and 0.2 mM sodium orthovanadate. Total cell lysates, each containing
60 mg of protein, were electrophoresed by SDS–7.5% polyacrylamide gel elec-
trophoresis (PAGE) and transferred to Immobilon-P membranes (Millipore).
The membranes were then probed with the relevant antibodies. These included
PDGFR-a and PDGFR-b (Santa Cruz Biotechnology), Akt/PKB, Phospho-Akt/
PKB (Ser473), total Bad, Phospho-Bad, total IkBa, and Phospho-IkBa (New
England Biolabs). Following incubation with horseradish peroxidase-conjugated
secondary antibody, bound proteins were detected by incubation with a chemi-
luminescent detection system (Pierce) as previously described (7). In order to
test for secreted PDGF in the conditioned medium, subconfluent HT1080 and
MCH603 cells were exposed to serum-free medium for 18 h. The conditioned
medium was then concentrated in the Centricon (Millipore) apparatus, followed
by PAGE under reducing or nonreducing conditions and immunoblotting, using
PDGF-A (E-10) and PDGF-B (P-20) antibodies (Santa Cruz Biotechnology).
Activated Ras, Rac1, and RhoA assays. Subconfluent cells were serum starved
for 18 h and then lysed with 1 3 Mg21 lysis buffer (Ras and Rac Activation Assay
Kits; Upstate Biotechnology). Each cell lysate (500 mg) was affinity precipitated
with 10 ml of Raf-1 RBD, PAK-1 PBD agarose, or glutathione S-transferase
(GST)-C21–Sepharose conjugate (43) at 4°C overnight for the Ras, Rac-Cdc42,
or RhoA activation assays, respectively. The beads were collected, washed, and
resuspended in 63 Laemmli sample buffer. Western blot analysis was performed
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as described elsewhere (7), using 1 mg of mouse monoclonal anti-Ras, anti-Rac1
(Upstate Biotechnology), and anti-RhoA (Santa Cruz Biotechnology) antibodies
per ml. Horseradish peroxidase-conjugated anti-mouse immunoglobulin G (San-
ta Cruz Biotechnology) was used as the secondary antibody. A chemilumines-
cence detection system (Pierce) was used for detection of the relevant proteins.
To determine the total Ras, Rac1, or RhoA levels, immunoblots were performed
using N-Ras(F155), Rac1(C-14), or RhoA(26C4) antibodies (Santa Cruz Bio-
technology) that recognize total protein.
Kinase assays. MEK, ERK, JNK, and Akt kinase assays were performed
according to the manufacturer’s protocols (New England Biolabs), using sub-
confluent cultures that had been serum starved (0.25% FCS) for 18 h, and have
been described elsewhere (18). Briefly, cells were washed twice with PBS,
scraped into 500 ml of lysis buffer, and incubated on ice for 20 min. After
centrifugation at 14,000 3 g for 20 min, the supernatants were incubated with the
relevant antibodies. The resulting immunoprecipitates were employed in kinase
assays. The activated MEK assay was carried out by incubating immunoprecipi-
tated phospho-MEK with ERK protein and cold ATP (New England Biolabs
MEK1/2Kinase Assay Kit). The activated ERK assay was carried out by incu-
bating immunoprecipitated phospho-ERK with Elk-1 fusion protein and cold
ATP (New England Biolabs p44/p42 ERK Assay Kit). The JNK assays were
carried out by incubating the JNK–c-Jun fusion protein complex with cold ATP
(New England Biolabs JNK/SAPK Assay Kit). The Akt-P assay was carried out
by incubating the immunoprecipitated total Akt with GSK3 protein and cold
ATP (New England Biolabs Akt Assay Kit). For MEK, ERK, and JNK assays,
the relevant gel was transferred onto an Immobilon membrane, and Western blot
analysis was performed. The blots were performed using phospho-ERK (Thr202/
Tyr204) monoclonal antibody for the MEK assay, phospho-Elk-1 (Ser383) poly-
clonal antibody for the ERK assay, phospho–c-Jun (Ser63) polyclonal antibody
for the JNK assay, and phospho-GSK3 a/b (Ser219) rabbit polyclonal antibody
for the Akt assay. The Raf-1 assay was performed as described by Graham et al.
(17). For the Raf-1 assay, the g-32P-labeled mitogen-activated protein (MAP)
Kinase (ERK) proteins in the gel were visualized by autoradiography. To deter-
mine the total Raf, MEK, ERK, JNK, and Akt levels, immunoblots were per-
formed using the respective antibodies that recognize total protein.
Elk-1 and NF-kB luciferase reporter assays. To measure Elk-1 activation, a
dual luciferase reporter assay kit (Promega) was used as previously described
(18). For NF-kB assays, approximately 2 3 105 parental HT1080 and MCH603
cells and the MCH603/PI3Kact or HT1080/PTEN stable transfectant cells were
cotransfected in six-well plates with the pUC13-based D56FosdE-luc plasmid
(measures basal expression but is not Ras responsive) and the NF-kB reporter,
(HIV-kB)3-luc (54). The latter plasmid has three tandem copies of the two
adjacent NF-kB sites from the human immunodeficiency virus enhancer (six total
tandem NF-kB sites) inserted just upstream of the minimal Fos promoter
present in D56FosdE-luc. The Effectene kit (Qiagen) was used for these transient
transfections. Following transfection, the cells were kept in serum-starved me-
dium for 24 h. Tumor necrosis factor alpha (TNF-a; 10 ng/ml) was then added
to the culture medium, and both treated and untreated control cultures were
incubated for a further 4-h period. The luciferase activity of each sample was
measured with the dual luciferase assay kit (Promega) and normalized with an
internal control Renilla luciferase.
Tumorigenicity assays. Cells were trypsinized and resuspended in 0.2 ml of
DMEM, and then 107 cells were injected subcutaneously into the flanks of 4- to
6-week-old nude athymic mice. Tumors were measured in three dimensions with
linear calipers at weekly intervals.
RESULTS
We have shown previously that HT1080 (mutant N-ras) cells
have constitutively active Raf-dependent (Raf/MEK/ERK/Elk-
1), Rac1 (Rac1/Cdc42/JNK), and RhoA signaling pathways
(18). Conversely, MCH603 (wild-type N-ras) cells have basal
levels of activity of these signal transduction proteins (18).
Interestingly, both HT1080 and MCH603 cells have significant
levels of constitutively active Akt. The fact that MCH603 does
not possess a mutant ras allele and yet has constitutively active
levels of Akt, approximating those found in HT1080 cells,
infers an alternative mechanism of chronic activation.
HT1080 and MCH603 constitutively secrete PDGF. Concen-
trated conditioned media and cell lysates from both HT1080
and MCH603 serum-starved cell cultures were electropho-
resed and immunoblotted with antibodies to PDGF-A and
PDGF-B. Both forms of PDGF were expressed at similar levels
by both cell types. However, whereas PDGF-A is secreted into
the medium, PDGF-B remains associated with the cells (Fig. 1A).
Analyses of PDGF dimers under nonreducing conditions indi-
cated that the predominant secreted form is PDGF-AA (data not
shown). Immunoblotting of cell lysates showed that both the a
and b forms of the PDGFR are expressed (Fig. 1B). Constitu-
tive secretion of PDGF-A and subsequent binding to and ac-
tivation of its cognate receptor is, therefore, the probable mech-
anism for downstream activation of PI 3-kinase and Akt. It is
known that the catalytic subunit of PI 3-kinase associates with,
and is activated by, the autophosphorylated PDGFR (20, 34, 46).
Modulation of PI 3-kinase and Akt/PKB activity. (i) HT1080
cells. We wished to downregulate constitutive activity of PI
3-kinase and/or Akt in HT1080 cells. Initially, we attempted
downregulation of PI 3-kinase activity via stable transfection
with PI 3-kinase dominant-negative cDNAs. Unfortunately,
none of the constructs tested (24) had the desired effect (data
not shown). Thus, we resorted to expressing the tumor sup-
pressor protein PTEN in these cells. PTEN is a dual-specificity
phosphatase that catalyzes the dephosphorylation of PIP3,
thereby inhibiting the activation of Akt (30). As shown in Fig.
2A, severalfold-higher levels of expression of PTEN were ob-
served in the HT1080/PTEN stable transfectants, compared to
parental HT1080 cells. Correspondingly, there was a decline in
the level of expression of activated phospho-Akt. This decline
in activity was confirmed in Akt assays (Fig. 3A).
(ii) MCH603 cells. Although these cells already express sig-
nificant levels of constitutively active Akt, and presumably PI
3-kinase, we wanted to elevate the activity levels even further
in order to determine if this may have an effect on in vitro
transformed phenotypic traits and in vivo tumorigenicity. To
accomplish this, MCH603 cells were stably transfected with a
constitutively activated PI 3-kinase–CAAX expression vector
(PI3Kact) that contains a myc epitope tag. As shown in Fig. 2B,
FIG. 1. Western blot analysis performed on HT1080 and MCH603
cell lysates or their respective conditioned media to determine the
levels of secreted PDGF-A and PDGF-B (A) or surface membrane-
bound PDGFR-a and PDGFR-b (B). HT, HT1080; 603, MCH603;
CM, conditioned medium.
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the transfectants express high levels of the myc epitope tag and,
correspondingly, higher levels of activated Akt.
Effects on other Ras-dependent signaling pathways. (i)
HT1080/PTEN cells. The lipid phosphatase activity of PTEN
dephosphorylates phosphoinositides and would be expected to
have inhibitory effects on PI 3-kinase-mediated activation of
RhoA-, Rac1-, and Raf-dependent signaling pathways. The
protein phosphatase acivity of this dual-specificity phosphatase
FIG. 2. Western blot analysis of the cell lysates from HT1080/PTEN transfectants (A) and MCH603/PI3Kact transfectants (B) to determine the
levels of PTEN (A), myc-tagged PI 3-kinase (B), phospho-Akt, and total Akt. Three independent HT1080/PTEN and MCH603/PI3Kact clones were
analyzed. The fold level of the individual proteins (PTEN and phospho-Akt) is relative to 1.0 for HT1080 control cells. HT, HT1080; 603, MCH603.
FIG. 3. In vitro Raf, MEK, ERK, and JNK kinase assays and Elk-1 activation assays performed on HT1080/PTEN (A) and MCH603/PI3Kact
(B) transfectants. For the kinase assays the fold level is relative to 1.0 for HT1080 control cells, and for the Elk-1 luciferase reporter the activities
are expressed as the percent relative to 100% for HT1080. Three independent HT1080/PTEN clones and MCH603/PI3Kact clones were analyzed.
HT, HT1080; 603, MCH603; V, vector only (control). The error bars indicate the standard deviations.
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may also have PIP3-independent effects on signal transduction.
In the case of the HT1080/PTEN transfectants, however, levels
of constitutively active RhoA, Rac1, and JNK and members of
the Raf-dependent pathway (Raf/MEK/ERK/Elk-1) remained
high, approximating the levels found in parental HT1080 cells
(Fig. 3A and 4). These levels of constitutive activity are pre-
sumably mediated by the mutant N-Ras protein (see Fig. 3A)
in a PI 3-kinase-independent manner.
(ii) MCH603/PI3Kact cells. Clear evidence of activation of
multiple signaling pathways was found in these cells (Fig. 3B
and 4). Persistent activation of RhoA, Rac1, and JNK and
members of the Raf-dependent pathway (Raf/MEK/ERK/
Elk-1) were observed. However, no activation of Ras was seen
(Fig. 4A). Thus, the activation of these pathways was indepen-
dent of Ras activation and was due either to direct signaling
from activated PI 3-kinase or via cross talk between members
of the distinct pathways. Quantitation of the levels of activity of
the various members of the signaling pathways examined re-
vealed approximately twofold-higher levels of Akt activity in
the transfectants, as expected. Levels of activated RhoA and
Rac1 approximated that seen in HT1080 cells. A modest but
reproducible increase in levels of activated Raf-1 (approxi-
mately 1.5-fold) and MEK (1.5- to 1.8-fold) over that seen in
HT1080 was observed. The levels of activated ERK and Elk-1
were approximately the same as seen in the HT1080 cells. All
levels of constitutive activity were markedly higher than those
found in the parental MCH603 cells.
Effects on NF-kB activation. Akt activation, either mediated
by PI 3-kinase or other signal transduction pathways, has been
shown to be an antiapoptotic survival factor via activation of
NF-kB and/or Bad (2, 27, 42). This property may well contrib-
ute to the tumor-forming properties of cancer cells. Thus, we
wished to determine if activation or downregulation of the
activities of these factors affected the tumorigenic phenotypes
of HT1080 and MCH603 cells. Akt activation has been re-
ported to activate NF-kB via IkB degradation (33, 42), al-
though other mechanisms of activation have been reported
(27, 44). In our studies we examined the status of IkB-a and
NF-kB in the parental and transfectant cells.
(i) IkB-a phosphorylation. Degradation of IkB subunits is
facilitated by their phosphorylation by IKK (22, 40, 48). Thus,
the level of phosphorylated IkB-a, relative to the levels of total
IkB-a protein, is indicative of the degradative process. In Fig.
5A we see that HT1080 and MCH603 have comparable levels
of phospho-IkB-a relative to the total IkB protein levels. In
contrast, the HT1080/PTEN transfectants clones have reduced
levels of phospho-IkB-a. Interestingly, the levels of total IkB-a
protein increased in these transfectants. Presumably, this is
due to the increased stability of the unphosphorylated IkB-a.
Thus, lowered Akt activity, mediated by the PTEN lipid phos-
phatase, results in decreased degradation of IkB-a.
The MCH603/PI3Kact transfectants exhibit the opposite
characteristics. Increased levels of phospho-IkB-a were seen
(Fig. 5B) with correspondingly greatly reduced levels of total
FIG. 4. Pull-down assays of activated Ras, Rac, and Rho. The GTP-bound forms of Ras, Rac, and Rho were pulled down with GST fusion
proteins, corresponding to the Ras-binding domain of Raf-1 (Raf-1 RBD), the p21-binding domain (PBD) of human PAK-1, and the C21 binding
domain of Rho, respectively, conjugated to agarose beads. The Ras-GTP, Rac-GTP, and Rho-GTP proteins bound to the beads were identified
using anti-Ras (A), anti-Rac (B), and anti-Rho (C) antibodies, respectively, in a Western immunoblot. Immunoblot analysis of total cell lysates
identified the levels of total protein.
FIG. 5. Western blot analysis performed on HT1080/PTEN transfectants (A) and MCH603/PI3Kact (B) transfectants to determine the levels
of phospho-IkB and total IkB in these cells.
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IkB-a protein. This is consistent with the increased levels of
constitutive Akt activity in these transfectants (Fig. 1B) and is
indicative of an increased rate of degradation of IkB-a protein,
presumably resulting in a release of IkB-bound NF-kB.
(ii) NF-kB activation. The levels of NF-kB activity in the
parental and transfectant cells were assayed, using an NF-kB
reporter assay (54). The relative fold activity was determined
using an internal control, the D56FosdE-luc expression vector.
Consistent with their essentially equal levels of constitutive
Akt activity, HT1080 and MCH603 cells had approximately the
same fold NF-kB activities. In the HT1080/PTEN transfectants
the level of activated NF-kB decreased but did not decline to
the level seen in normal human diploid fibroblast (HDF) cells
(Fig. 6A). Since the RhoA, Rac1, and Raf signaling pathways
remain constitutively active in HT1080 cells, we interpret this
to indicate that activation of NF-kB occurs via Akt-dependent
and -independent pathways in these cells. In an attempt to
clarify this further, we treated the various cell lines with TNF-
a, a cytokine that stimulates NF-kB activation via multiple
pathways (15, 22). Both HT1080 and HT1080/PTEN NF-kB
activity levels were elevated by TNF-a, whereas the level of
NF-kB activity in MCH603 cells was unaffected by TNF-a (Fig.
6B). However, the level of NF-kB activity in the MCH603/
PI3Kact transfectants was substantially increased in the pres-
ence of TNF-a (Fig. 6B). It should be noted here that the
MCH603/PI3Kact cells possess constitutively active RhoA,
Rac1, and Raf pathways but not constitutively active Ras (Fig.
3 and 4). Taken together, these data suggest that NF-kB acti-
vation in MCH603 cells is Akt dependent, whereas in HT1080
and MCH603/PI3Kact cells activation is mediated by both Akt-
dependent and independent pathways.
Effects on Bad. Another mechanism whereby activated Akt
may function as a survival factor is by phosphorylating the
proapoptotic protein Bad, thereby inactivating it and inhibit-
ing the Bad-mediated apoptotic pathway (13). This is, indeed,
what was observed: the levels of phosphorylated Bad de-
creased in the HT1080/PTEN transfectants and increased in
the MCH603/PI3Kact transfectants, relative to their respective
parental cells (Fig. 7).
Biological effects of modulating PI 3-kinase and Akt activity.
Activation of PI 3-kinase has been shown to have dramatic
effects on the biological behavior of cells, including the trans-
formation of rodent cells (24). We therefore examined a num-
ber of phenotypic traits expressed in culture that are associated
with neoplastic transformation, plus tumorigenic growth in vivo.
(i) Actin stress fibers. We had earlier shown (18), as is il-
lustrated in Fig. 8A and B, that HT1080 cells have disorganized
actin, whereas MCH603 cells have restored an extensive cy-
toskeleton of actin stress fibers. There was no restoration of
actin stress fibers in the HT1080/PTEN transfectants (Fig. 8C).
Thus, it appears that phosphoinositide-mediated activation of
the Akt pathway is not the determining factor with respect to
FIG. 6. In vitro luciferase reporter assays were performed to de-
termine NF-kB activities in HT1080, HT1080/PTEN, MCH603, and
MCH603/PI3Kact cells with (B) or without (A) TNF-a (TNF) treat-
ment. Normal HDFs were used as a control for basal level activity. The
NF-kB luciferase reporter activities are presented as the average fold
activation. HT, HT1080; 603, MCH603.
FIG. 7. Western blot analysis performed on HT1080/PTEN transfectants (A) and 603/PI3Kact transfectants (B) to determine the level of
Phospho-Bad and total Bad in these cells relative to the levels in the parental HT1080 and MCH603 cells.
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regulation of actin stress fiber formation. However, as seen in
Fig. 8D, increased activation of Akt in the MCH603/PI3Kact
transfectants is associated with a dramatic loss of actin stress
fibers. It should be noted that these cells have also constitu-
tively activated RhoA, Rac1, and Raf/MEK/ERK/Elk-1 signal-
ing pathways (Fig. 3 and 4) and, therefore, more closely re-
semble HT1080 cells in this regard.
(ii) Anchorage-independent growth. Our earlier studies had
shown that HT1080 cells grow well in soft agar, whereas
MCH603 cells are incapable of forming colonies in this me-
dium (18). Downregulation of constitutive Akt activity in the
HT1080/PTEN transfectants had no effect on this ability to
form colonies in soft agar (Fig. 9), whereas MCH603/PI3Kact
transfectants had a partially restored ability to grow. Colonies
were able to form when cells were plated at high density (106
cells per dish) but not when plated at low density (104 cells per
dish). The HT1080 cells form colonies at both plating densities.
It should again be noted that the expression of PI3Kact in the
transfectants activates the RhoA, Rac1, and Raf/MEK/ERK/
Elk-1 signaling pathways (Fig. 3 and 4). These same pathways
remain constitutively active in the HT1080/PTEN transfec-
tants. Thus, the partial restoration of anchorage-independent
growth is not dependent on the constitutive activity of Akt per
se but is associated with activation of other Ras-associated
signaling pathways.
(iii) Tumor formation. HT1080 and MCH603 cells both
form tumors in immune-deficient mice. However, the kinetics
of tumor formation differ dramatically. HT1080 cells form
aggressively growing tumors that reach a large size within 3
weeks, whereas MCH603 cells form tumors much more slowly.
We have termed these phenotypes as aggressive and weak
tumorigenic phenotypes, respectively (18, 35). Stable elevated
levels of expression of the tumor suppressor protein PTEN in
HT1080/PTEN transfectants had no effect on the aggressive
tumorigenic phenotype (Fig. 10A). Conversely, elevated levels
of activated PI 3-kinase protein in the MCH603/PI3Kact trans-
fectants resulted in a conversion from a weak to an aggressive
tumorigenic phenotype, albeit not one as aggressive as that
seen with HT1080 and HT1080/PTEN cells (Fig. 10B). As with
the other biological phenotypes examined, the aggressive and
weak tumorigenic phenotypes cannot be a direct consequence
of PI 3-kinase or Akt activity. Thus, the antiapoptotic function
of NF-kB and inactivation of the proapoptotic factor, Bad, do
not seem to influence the aggressive and weak tumorigenic
phenotypes of HT1080 and MCH603, respectively. As dis-
cussed in more detail below, the activation of MEK in the
MCH603/PI3Kact transfectants is a likely candidate for orches-
trating the conversion from weak to aggressive tumor-forming
ability.
DISCUSSION
We have developed an experimental model system that uti-
lizes the HT1080 human fibrosarcoma cell line, possessing a
mutant N-ras allele, and its derivative, MCH603, in which the
mutant N-ras allele has been deleted (35). In the HT1080 cells
all Ras-dependent pathways examined, namely, the Raf, Rac1,
RhoA, and PI 3-kinase/Akt pathways, were constitutively ac-
tive, presumably as a consequence of the permanent activated
FIG. 8. Actin stress fiber organization in HT1080, MCH603,
HT1080/PTEN, and MCH603/PI3Kact cells. The cells were stained
with fluorescein-conjugated phalloidin. Magnification, 3160.
FIG. 9. Anchorage-independent assays. Totals of 104 cells (A) or 106 cells (B) were plated per 60-mm petri dish in soft agar. Colonies (.0.1
mm) were counted after incubation for 3 weeks at 37°C, with periodic refeeding with fresh growth medium. The error bars indicate standard
deviations.
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status of the mutant N-Ras protein (18). In contrast, the de-
rivative MCH603 cells exhibit only basal levels of activity of
these pathways, with the singular exception of Akt and p38
MAP kinase. We show here that this is probably due to con-
stitutive expression of PDGF and the activation of its cognate
PDGFR.
Elevated levels of expression of the lipid phosphatase PTEN
protein in HT1080 cells resulted in a significant decrease in
activity of Akt. This indicates that the constitutive activation of
Akt is mediated via PI 3-kinase generated PIP3, rather than
some other pathway, for example Ca21-calmodulin-dependent
protein kinase II (53). Although Akt activity was significantly
decreased, the levels of constitutive activity of the RhoA-,
Rac1-, and Raf-dependent pathways remained high. Presum-
ably, this is due to the continued stimulation by the endoge-
nous mutant N-Ras protein, whose constitutive activity was
unaffected by PTEN.
It is interesting that elevated levels of expression of the
PTEN protein did not affect the proliferation of the HT1080/
PTEN transfectants, since others have reported that overex-
pression of PTEN induces G1 arrest and/or apoptosis (12, 16).
However, most of these studies employed transient-transfec-
tion methodologies. Also, the cell lines examined were null for
PTEN activity (37). Stable transfections of endogenous wild-
type PTEN glioma cells with wild-type PTEN cDNA and its
subsequent overexpression did not noticeably affect the prolif-
eration of the cells in culture (16). We experienced a similar
lack of effect on the growth of HT1080 cells, which are PTEN
wild type (data not shown), even though the HT1080/PTEN
transfectants express severalfold-higher levels of PTEN pro-
tein than the endogenous levels of wild-type PTEN expressed
in HT1080. However, the increased levels of PTEN protein did
correspond with a decrease in Akt activity. This suggests that
the physiological level of endogenous wild-type PTEN in both
HT1080 and MCH603 cells did not influence the PIP3-medi-
ated constitutive activation of Akt and further suggests that a
threshold level of PTEN protein is required for its inhibitory
effect.
Elevating the level of activity of PI 3-kinase in the MCH603/
PI3Kact transfectants had dramatic effects on the constitutive
activities of other putative Ras-dependent pathways examined.
The RhoA-, Rac1-, and Raf-dependent pathways were all ac-
tivated, presumably in an activated PI 3-kinase-dependent
fashion involving positive cross talk (47, 51). Interestingly, en-
dogenous Ras was not activated. There has been some debate
as to whether low or high levels of activated PI 3-kinase stim-
ulate the activation of Ras (51). In these cells there is clearly no
activation of endogenous Ras: thus, PI 3-kinase-mediated ac-
tivation of these “Ras-dependent” pathways occurs down-
stream of Ras. It is noteworthy that activation of members of
the Raf pathway, in particular MEK, exceeded the levels seen
in HT1080 cells even though Ras itself was not activated.
The fact that MCH603 cells have significant levels of Akt
activity, which is PI 3-kinase mediated, and yet do not exhibit
activation of the RhoA-, Rac1-, and Raf-dependent pathways,
suggests that a threshold level of activation is required to
initiate the cross talk activation of multiple pathways. Whether
this reflects an on/off switch to the activated state, as posited by
Ferrell (14), will require further experimentation to determine.
PI 3-kinase-mediated activation of Akt and its subsequent
upregulation of the activity of the transcription factor, NF-kB,
have been shown to be important modulators of antiapoptotic
cell survival (33, 42). Additionally, both Akt and PI 3-kinase, in
their activated form, have been shown to have transforming
activity in experimental rodent and avian cell systems (2, 11,
24).
Examination of NF-kB activity in the HT1080 and MCH603
parental and HT1080/PTEN and MCH603/PI3Kact transfec-
tant cells revealed evidence of complex, multiple pathways of
regulation. The complexity of NF-kB activation has been ad-
dressed by many investigators. Activation may be effected by
oncogenic Ras through Raf-dependent and Raf-independent
MAP kinase signaling pathways (15, 19, 32). The Raf-indepen-
dent pathway appears to signal via Rac and p38 or a closely
related kinase. Raf-dependent activation also converges with
Raf-independent activation at the level of p38 activation. Fur-
thermore, activation may be effected by PI 3-kinase, either as
a consequence of activation of PI 3-kinase by oncogenic Ras or
independently of Ras (27, 44).
In the case of the parental HT1080 and MCH603 cells, the
basal levels of NF-kB activity were similar and significantly
higher than those of normal HDFs. The fact that HT1080 and
MCH603 cells have similar levels of constitutive activity of
NF-kB under conditions of serum starvation is interesting,
given that HT1080 has the capacity to stimulate activity via
oncogenic Ras-dependent signaling, as well as PDGF-medi-
FIG. 10. Tumorigenicity assays of HT1080, MCH603, HT1080/
PTEN, and 603/PI3Kact cells. Each point is the average size of the
tumor sizes of all sites inoculated (total of 6 for the parental cells and
18 for the transfectants, combining three independent clones).
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ated PI 3-kinase and Akt signaling, whereas MCH603 cells
possess only the latter mechanism. This presumably reflects an
upper threshold level of activity under this physiological con-
dition. In both HT1080 and MCH603 cells, activation of
NF-kB appears to be associated with, and presumably depen-
dent upon, IkB degradation and the release of NF-kB seques-
tered in the cytosol. The parental HT1080 and MCH603 cells,
however, differ dramatically in their responsiveness to TNF-a
stimulation of NF-kB activity. Whereas the activity in HT1080
cells is amplified manyfold, the activity in MCH603 cells is
unaltered, as is the case with HDF cells. Thus, it would seem
that TNF-a stimulatory effects are mediated only through on-
cogenic Ras or one or more downstream signaling partners,
independently of PI 3-kinase-mediated Akt activation.
Support for this notion is given by the fact that elevated
PTEN expression in HT1080/PTEN transfectants reduces the
level of constitutive NF-kB activity below that seen in
MCH603 cells but not to the level seen in HDFs. This indicates
that the constitutive activation of NF-kB in HT1080 is depen-
dent on both PI 3-kinase/Akt and oncogenic Ras signaling.
Also, overexpression of activated PI 3-kinase in MCH603/
PI3Kact transfectants results in levels of constitutive NF-kB
activity that are somewhat higher than those seen in MCH603
or HT1080 cells. In these cells exposure to TNF-a does result
in an amplification of NF-kB activity to levels approximating
those seen in TNF-a-stimulated HT1080 cells. This result is
consistent with the observation that the RhoA, Rac1 and Raf
signaling pathways all become constitutively activated in these
transfectants. It also indicates that Ras-GTP per se is not
directly required for TNF-a-mediated stimulation.
A major goal of this study was to determine whether con-
stitutive activation of PI 3-kinase and Akt contributed to the
aggressive tumorigenic phenotype of HT1080 fibrosarcoma
cells. Our data, which are summarized in Fig. 11, clearly dem-
onstrate that downregulation of this antiapoptotic survival
pathway does not demonstrably affect the aggressive tumori-
genic phenotype in HT1080/PTEN transfectants. The fact that
the HT1080/PTEN transfectants retain the oncogenic Ras-
dependent constitutive activation of the RhoA, Rac1, and Raf
signaling pathways seems the most likely mechanism for re-
taining the aggressive tumorigenic phenotype. Consistent with
this notion is the observation that overexpression of activated
PI 3-kinase in the MCH603/PI3Kact transfectants results in
constitutive activation of the RhoA-, Rac1-, and Raf-depen-
dent signaling pathways, accompanied by a conversion from
the weak to the aggressive tumorigenic phenotype (Fig. 11).
In earlier studies we have shown that, in the absence of
mutant N-Ras in the MCH603 cells, overexpression of acti-
FIG. 11. Summary of levels of constitutive activity of members of the PI 3-kinase, RhoA, Rac1, and Raf signaling pathways and of the
tumorigenic phenotypes in parental HT1080 and MCH603 cells and their respective transfectants, HT1080/PTEN and MCH603/PI3Kact. p, Pro-
teins constitutively active in HT1080 or MCH603;2 or1, decrease or increase, respectively, in the constitutive activity of individual factors tested
in HT1080/PTEN and MCH603/PI3Kact relative to their respective parental cells;11, activity higher than that seen in HT1080 cells; ‡, not tested.
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vated MEK results in the conversion to an aggressive tumori-
genic phenotype (18). This overexpression, coupled with a lack
of effect when activated Raf or Rac1 were expressed, led us to
speculate that the overexpression of activated MEK in these
cells stimulated the activation of a possibly novel pathway that
is critical for the conversion to an aggressive tumorigenic
phenotype. Consistent with this notion is the observation in
this study that the levels of endogenous activated MEK in
MCH603/PI3Kact transfectants are higher than that seen in
HT1080 cells. Thus, the same putative novel pathway may be
activated in these cells. Further experimentation is required to
test this hypothesis.
The generality of the phenomena described here with re-
spect to other human cancers and cell lines must await further
examination. If a novel pathway is confirmed and found to be
general for human cancers that express mutant Ras proteins,
this may provide an important target for cancer therapy.
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